Recombinant human erythropoietin (rhEPO), with supplement of other iron agents (such as dextran), is used to promote erythropoiesis and eliminate the iron utilization obstacle for the RBC thrombocytopenia and anemia. Here, EPO is linked to anemia (phenotype).